This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Podlisny, M. B. Articles by Selkoe, D. J. Search for Related Content PubMed PubMed Citation Articles by Podlisny, M. B. Articles by Selkoe, D. J.

American Journal of Pathology, Vol 142, 17-24, Copyright © 1993 by American Society for Investigative Pathology

REGULAR ARTICLES

Microinjection of synthetic amyloid beta-protein in monkey cerebral cortex fails to produce acute neurotoxicity

MB Podlisny, DT Stephenson, MP Frosch, DR Tolan, I Lieberburg, JA Clemens and DJ Selkoe
Department of Neurology, Harvard Medical School, Boston, Massachusetts.

The cerebral deposition of amyloid beta protein (A beta P) is an early pathogenetic event in Alzheimer's disease (AD). Recent studies suggest both neurotoxic and neurotrophic effects of A beta P in vitro. Because progressive A beta P deposition and surrounding neuritic dystrophy occur spontaneously in primates, we evaluated the in vivo effects of synthetic A beta P in monkey cortex. Experimental and control (reverse or substituted) peptides were stereotactically injected into multiple neocortical sites of adult rhesus monkeys in a vehicle of either artificial cerebrospinal fluid or acetonitrile. After 2 weeks, all injection sites were identified and characterized. A beta P antibodies specifically detected the injected A beta P1-40 peptide. Serial sections stained with silver and antineurofilament protein demonstrated comparable degrees of degenerating neurons, dystrophic neurites, and axonal spheroids associated with both experimental and control peptide injections. Alz 50 staining was sparse or absent in all sites. Similar results were obtained in an animal killed 3 months after injection. We conclude that specific cellular changes closely resembling the pathology of Alzheimer's disease were not detected in these acute experiments, and that control and experimental A beta P peptides produced indistinguishable effects.

This article has been cited by other articles:

				Y.-H. Suh and F. Checler Amyloid Precursor Protein, Presenilins, and alpha -Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease Pharmacol. Rev., September 1, 2002; 54(3): 469 - 525. [Abstract] [Full Text] [PDF]

				H.-S. KIM, C. H. PARK, S. H. CHA, J.-H. LEE, S. LEE, Y. KIM, J.-C. RAH, S.-J. JEONG, and Y.-H. SUH Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity FASEB J, August 1, 2000; 14(11): 1508 - 1517. [Abstract] [Full Text]

				M. B. Podlisny, B. L. Ostaszewski, S. L. Squazzo, E. H. Koo, R. E. Rydell, D. B. Teplow, and D. J. Selkoe Aggregation of Secreted Amyloid [IMAGE]-Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture J. Biol. Chem., April 21, 1995; 270(16): 9564 - 9570. [Abstract] [Full Text] [PDF]

				Y. H. Chong, J. H. Sung, S. A. Shin, J.-H. Chung, and Y.-H. Suh Effects of the beta -Amyloid and Carboxyl-terminal Fragment of Alzheimer's Amyloid Precursor Protein on the Production of the Tumor Necrosis Factor-alpha and Matrix Metalloproteinase-9 by Human Monocytic THP-1 J. Biol. Chem., June 22, 2001; 276(26): 23511 - 23517. [Abstract] [Full Text] [PDF]